Evidence map›Paper›PMID 37749501›Full record

Observational studyBMC infectious diseases2023

Clinical and microbiological characterization of Salmonella spp. isolates from patients treated in a university hospital in South America between 2012-2021: a cohort study.

Fernando Rosso, David E Rebellón-Sánchez, Julio Llanos-Torres, Leidy Johanna Hurtado-Bermudez, Laura Ayerbe, John Harold Suárez, Nicolás Orozco-Echeverri, Cristhian Camilo Rojas-Perdomo, Isabel Lucia Zapata-Vasquez, Jaime Patiño-Niño and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Carbapenem-resistantFrontiers in cellular and infection microbiology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Prevalence, Serotypes and Antimicrobial Resistance ofInfection and drug resistance · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fernando RossoFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia. fernando.rosso@fvl.org.co.
David E Rebellón-SánchezFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia. david.rebellon@fvl.org.co.
Julio Llanos-TorresFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia.
Leidy Johanna Hurtado-BermudezFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia.
Laura AyerbeUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, 760031, Colombia.
John Harold SuárezUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, 760031, Colombia.
Nicolás Orozco-EcheverriUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, 760031, Colombia.
Cristhian Camilo Rojas-PerdomoUniversidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, 760031, Colombia.
Isabel Lucia Zapata-VasquezFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia.
Jaime Patiño-NiñoFundación Valle del Lili, Cali, Departamento de Pediatría, Servicio de Enfermedades Infecciosas, Carrera 98 #18-49, 760031, Cali, Colombia.
Luis Gabriel Parra-LaraFundación Valle del Lili, Centro de Investigaciones Clínicas (CIC), Carrera 98 #18-49, 760031, Cali, Colombia.
Fundación Valle del Lili · COIcesi University · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalmonellosis is a major cause of morbidity and mortality and one of the most frequent etiologies of diarrhea in the world. Mortality due to Salmonellosis in Latin America still poorly understood, and there is a lack of studies that evaluate resistance and clinical manifestations. The aims of this study were to characterize patients infected with Salmonella spp. seen in a university hospital in Colombia between 2012 and 2021, to evaluate trends in antibiotic resistance and to determine the proportion of overall mortality and related factors.

methodsRetrospective observational study. All patients with microbiological diagnosis of Salmonella spp. were included. The sociodemographic, clinical and microbiological characteristics were described, and the proportion of antibiotic resistant isolates per year was estimated. The prevalence of mortality according to age groups was calculated. Log binomial regression models were used to establish factors associated with mortality.

resultsFive hundred twenty-two patients were analyzed. Salmonellosis accounted for 0.01% of all medical consultations. The median age was 16 years old. The most common clinical presentation was gastroenteric syndrome (77.1%) and symptoms included diarrhea (79.1%), fever (66.7%), abdominal pain (39.6%) and vomiting (35.2%). Of the Salmonella spp. isolates, 78.2% were not classified, 19.1% corresponded to non-typhoidal Salmonella and 2.7% to Salmonella typhi. Mortality occurs in 4.02% of the patients and was higher in patients with hematologic malignancy (11.6%). When analyzing by age group, the proportion of deaths was 2.8% in patients aged 15 years or younger, while in those older than 15 years it was 5.4%. Factors associated to mortality where bacteremia (aPR = 3.41 CI95%: 1.08-10.76) and to require treatment in the ICU (aPR = 8.13 CI95%: 1.82-37.76). In the last 10 years there has been a steady increase in resistance rates to ciprofloxacin, ampicillin, ampicillin/sulbactam and ceftriaxone, reaching rates above 60% in recent years.

conclusionsDespite improved availability of antibiotics for the treatment of salmonellosis in the past decades, mortality due to salmonellosis continues occurring in children and adults, mainly in patients with hematological malignancies and bacteremia. Antibiotic resistance rates have increased significantly over the last 10 years. Public health strategies for the control of this disease should be strengthened, especially in vulnerable populations.

Indexed as

BacteremiaSalmonella InfectionsAdolescentAdultAmpicillinAnti-Bacterial AgentsChildCohort StudiesDiarrheaHospitals, UniversityHumansRetrospective StudiesSalmonellaSouth AmericaAmpicillinAnti-Bacterial AgentsFoodborne diseasesSalmonellaSalmonella infectionsSalmonella typhi

Identifiers

PMID37749501
PMCPMC10519077
OpenAlexW4387024297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.